ADTX
Aditxt Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
262,660
P/E Ratio
—
EPS
$-2828.18
Beta
-17.50
52W High
$53453.52
52W Low
$0.47
50-Day MA
$13.91
200-Day MA
$6077.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
0.35
PEG Ratio
—
About Aditxt Inc.
Aditxt Inc. is a pioneering biotechnology company focused on revolutionizing healthcare through its proprietary immune modulation and personalized medicine platform. The firm is committed to enhancing immune responses to tackle chronic diseases and allergies, thereby improving patient outcomes. With a promising pipeline of therapeutic candidates, strengthened by rigorous research and strategic partnerships, Aditxt is well-positioned to lead in the emerging sector of immune-based therapies. Emphasizing scientific innovation and patient-centric solutions, the company aims to make a significant impact on both immunology and the overall healthcare landscape.
Fundamentals
| Revenue (TTM) | 14,340 |
| Gross Profit (TTM) | 2,852 |
| EBITDA | $-18.08M |
| Operating Margin | -35874.00% |
| Return on Equity | -699.00% |
| Return on Assets | -50.80% |
| Revenue/Share (TTM) | $0.37 |
| Book Value | $368.06 |
| Price-to-Book | 0.05 |
| Price-to-Sales (TTM) | 18.32 |
| EV/Revenue | 134.68 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1094.00% |
| Shares Outstanding | 510,120 |
| Float | 798,090 |
| % Insiders | 0.09% |
| % Institutions | 0.22% |
More HEALTHCARE Stocks
Data last updated: 5/25/2026